| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
61,781 |
59,428 |
$3.38M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
64,472 |
62,353 |
$3.20M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
22,580 |
22,182 |
$1.64M |
| 64635 |
|
1,919 |
1,792 |
$582K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
4,720 |
4,716 |
$525K |
| 64636 |
|
1,668 |
1,550 |
$399K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
2,331 |
2,329 |
$395K |
| 80050 |
General health panel |
10,592 |
10,546 |
$343K |
| 96127 |
|
67,969 |
65,841 |
$264K |
| 99406 |
|
17,868 |
17,365 |
$237K |
| 64493 |
|
1,380 |
1,247 |
$227K |
| J0475 |
Injection, baclofen, 10 mg |
407 |
403 |
$168K |
| 64483 |
|
842 |
836 |
$165K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
5,804 |
5,790 |
$154K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,226 |
1,216 |
$118K |
| 64494 |
|
1,181 |
1,068 |
$101K |
| 62323 |
|
526 |
522 |
$90K |
| 80061 |
Lipid panel |
7,040 |
7,031 |
$85K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
9,081 |
9,063 |
$80K |
| 82607 |
|
5,514 |
5,502 |
$74K |
| 84403 |
|
3,087 |
3,076 |
$73K |
| 99152 |
|
3,732 |
3,515 |
$70K |
| 84402 |
|
2,570 |
2,561 |
$60K |
| 62321 |
|
271 |
271 |
$51K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
4,654 |
4,411 |
$42K |
| 82627 |
|
2,095 |
2,093 |
$42K |
| 84270 |
|
2,161 |
2,153 |
$41K |
| 64633 |
|
124 |
123 |
$36K |
| 83970 |
|
756 |
756 |
$31K |
| 84480 |
|
2,455 |
2,454 |
$31K |
| 82670 |
|
1,019 |
1,019 |
$29K |
| 82746 |
|
1,920 |
1,919 |
$26K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
185 |
185 |
$24K |
| 64495 |
|
216 |
200 |
$23K |
| 20610 |
|
501 |
494 |
$22K |
| 64490 |
|
124 |
110 |
$22K |
| 80400 |
|
713 |
711 |
$20K |
| 62369 |
|
479 |
471 |
$20K |
| 84436 |
|
3,082 |
3,079 |
$19K |
| 64634 |
|
70 |
70 |
$18K |
| 86140 |
|
3,471 |
3,462 |
$16K |
| 84234 |
|
248 |
248 |
$16K |
| 84481 |
|
935 |
931 |
$15K |
| 83001 |
|
670 |
669 |
$12K |
| 83002 |
|
665 |
664 |
$12K |
| 82533 |
|
850 |
850 |
$12K |
| 84439 |
|
1,413 |
1,409 |
$12K |
| 77002 |
|
175 |
172 |
$11K |
| 64491 |
|
99 |
92 |
$9K |
| 84146 |
|
349 |
348 |
$7K |
| 62370 |
|
158 |
158 |
$7K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
3,710 |
3,432 |
$6K |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
788 |
655 |
$6K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
875 |
866 |
$5K |
| 83735 |
|
646 |
645 |
$4K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
58 |
58 |
$4K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
336 |
331 |
$4K |
| 83615 |
|
583 |
582 |
$4K |
| 84144 |
|
140 |
140 |
$3K |
| 99490 |
Ccm add 20min |
848 |
848 |
$3K |
| 82728 |
|
207 |
207 |
$3K |
| 84153 |
|
162 |
162 |
$3K |
| 64492 |
|
29 |
26 |
$3K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
218 |
215 |
$2K |
| 84443 |
Thyroid stimulating hormone (TSH) |
98 |
98 |
$2K |
| 84100 |
|
324 |
323 |
$2K |
| 82248 |
|
300 |
299 |
$2K |
| 84550 |
|
312 |
311 |
$1K |
| 80053 |
Comprehensive metabolic panel |
120 |
120 |
$1K |
| 64450 |
|
26 |
24 |
$936.42 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
1,355 |
1,293 |
$847.77 |
| 76942 |
|
16 |
14 |
$558.98 |
| 84479 |
|
52 |
52 |
$341.89 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,532 |
2,347 |
$249.56 |
| 84450 |
|
45 |
45 |
$236.70 |
| 82550 |
|
39 |
39 |
$228.90 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
76 |
76 |
$169.18 |
| 84460 |
|
26 |
26 |
$139.88 |
| 36415 |
Collection of venous blood by venipuncture |
17 |
17 |
$125.97 |
| 82040 |
|
30 |
30 |
$124.78 |
| 82247 |
|
18 |
18 |
$91.62 |
| 82310 |
|
17 |
17 |
$89.08 |
| 84132 |
|
18 |
18 |
$84.06 |
| 84075 |
|
13 |
13 |
$68.38 |
| 82947 |
|
16 |
16 |
$63.84 |
| 84155 |
|
17 |
17 |
$63.41 |
| J2704 |
Injection, propofol, 10 mg |
172 |
139 |
$15.08 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
20 |
19 |
$0.40 |